Comparison of micafungin and fluconazole for experimental Candida keratitis in rabbits

Cornea

Volumn 26, Issue 3, 2007, Pages 336-342

  Hiraoka, Takahiro ^a   Kaji, Yuichi ^a   Wakabayashi, Taketoshi ^a   Nanbu, Patricia N ^a   Okamoto, Fumiki ^a   Oshika, Tetsuro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Candida albicans; Fluconazole; Fungal keratitis; Micafungin; Subconjunctival injection

Indexed keywords

FLUCONAZOLE; MICAFUNGIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS KERATITIS; CONTROLLED STUDY; CORNEA STROMA; DRUG EFFICACY; HISTOPATHOLOGY; KERATITIS; MALE; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RANDOMIZATION;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDIASIS; CONJUNCTIVA; DISEASE MODELS, ANIMAL; EYE INFECTIONS, FUNGAL; FLUCONAZOLE; INJECTIONS; KERATITIS; LIPOPROTEINS; MALE; PEPTIDES, CYCLIC; RABBITS;

EID: 34147142297     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31802cd8a8     Document Type: Article

References (48)

1. Hyndiuk RA, Yee RW. Antifungal agents. In: Tabbara KF, Hyndiuk RA, eds. Infections of the Eye. Boston: Little, Brown; 1986:239-256.
2. Jones BR. Principles in the management of oculomycosis. XXXI Edward Jackson memorial lecture. Am J Ophthalmol. 1975;79:719-751.
3. Ishibashi Y. Keratomycosis in Japan reported from 1976 to 1980. Nippon Ganka Gakkai Zasshi. 1982;86:651-656.
4. O'Brien TP, Green WR. Fungus infections of the eye and periocular tissues. In: Garner A, Klintworth GK, eds. Pathobiology of Ocular Disease: A Dynamic Approach, Part A. 2nd ed. New York: Marcel Dekker; 1994:299-333.
5. Savani DV, Perfect JR, Cobo LM, et al. Penetration of new azole compounds in to the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother. 1987;31:6-10.
6. Panda A, Sharma N, Angra SK. Topical fluconazole therapy of Candida keratitis. Cornea. 1996;15:373-375.
7. Behrens-Baumann W, Klinge B, Ruchel R. Topical fluconazole for experimental Candida keratitis in rabbits. Br J Ophthalmol. 1990;74:40-42.
8. Yee RW, Cheng CJ, Meenakshi S, et al. Ocular penetration and pharmacokinetics of topical fluconazole. Cornea. 1997;16:64-71.
9. Abbasoglu OE, Hosal BM, Sener B, et al. Penetration of topical fluconazole into human aqueous humor. Exp Eye Res. 2001;72:147-151.
10. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother. 2000;44:57-62.
11. Ikeda F, Wakai Y, Matsumoto S, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother. 2000;44:614-618.
12. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 2002;46:1857-1869.
13. Matsumoto S, Wakai Y, Nakai T, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother. 2000;44:619-621.
14. Huang A, Edwards F, Bernard EM, et al. In vitro activity of the new semisynthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species. Eur J Clin Microbiol Infect Dis. 1990;9:697-699.
15. Vazquez JA, Lynch M, Sobel JD. In vitro activity of a new pneumocandin antifungal agent, L-733,560 against azole-susceptible and -resistant Candida and Torulopsis species. Antimicrob Agents Chemother. 1995;39:2689-2691.
16. Verweij PE, Oakley KL, Morrissey J, et al. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother. 1998;42:873-878.
17. Tomishima M, Ohki H, Yamada A, et al. FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. J Antibiot. 1999;52:674-676.
18. Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362:1142-1151.
19. National Research Council, Committee on the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources, Commission on Life Sciences. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
20. Ishibashi Y, Kaufman HE. The effects of subconjunctival miconazole in the treatment of experimental Candida keratitis in rabbits. Arch Ophthalmol. 1985;103:1570-1573.
21. Ray WA, O'Day DM, Head WS, et al. Variability in isolate recovery rates from multiple and single breeds of outbred pigmented rabbits in an experimental model of Candida keratitis. Curr Eye Res. 1984;3:949-953.
22. Foster CS, Lass JH, Moran-Wallace K, et al. Ocular toxicity of topical antifungal agents. Arch Ophthalmol. 1981;99:1081-1084.
23. O'Day DM, Ray WA, Head WS, et al. Influence of the corneal epithelium on the efficacy of topical antifungal agents. Invest Ophthalmol Vis Sci. 1984;25:855-859.
24. O'Day DM, Head WS, Robinson RD, et al. Corneal penetration of topical amphotericin B and natamycin. Curr Eye Res. 1986;5:877-882.
25. Urbak SF, Degn T. Fluconazole in the management of fungal ocular infections. Ophthalmologica. 1994;208:147-156.
26. Sonego-Krone S, Sanchez-Di Martino D, Ayala-Lugo R, et al. Clinical results of topical fluconazole for the treatment of filamentous fungal keratitis. Graefes Arch Clin Exp Ophthalmol. 2006;244:782-787.
27. Holgado S, Luna JD, Juarez CP. Postoperative candida keratitis treated successfully with fluconazole. Ophthalmic Surg. 1993;24:132.
28. Yilmaz S, Maden A. Severe fungal keratitis treated with subconjunctival fluconazole. Am J Ophthalmol. 2005;140:454-458.
29. Foster CS. Miconazole therapy for keratomycosis. Am J Ophthalmol. 1981;91:622-629.
30. Fitzsimons R, Peters AL. Miconazole and ketoconazole as a satisfactory first-line treatment for keratomycosis. Am J Ophthalmol. 1986;101:605-608.
31. Leck AK, Thomas PA, Hagan M, et al. Aetiology of suppurative corneal ulcers in Ghana and south India, and epidemiology of fungal keratitis. Br J Ophthalmol. 2002;86:1211-1215.
32. Wang L, Zhang Y, Wang Y, et al. Spectrum of mycotic keratitis in China. Zhonghua Yan Ke Za Zhi. 2000;36:138-140.
33. Chander J, Sharma A. Prevalence of fungal corneal ulcers in northern India. Infection. 1994;22:207-209.
34. Hitchcock CA, Pye GW, Troke PF, et al. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother. 1993;37:1962-1965.
35. Ruhnke M, Eigler A, Tennagen I, et al. Emergence of fluconazoleresistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol. 1994;32:2092-2098.
36. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia. 2001;150:101-115.
37. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36:630-637.
38. Reis A, Sundmacher R, Tintelnot K, et al. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol. 2000;84:932-933.
39. Polizzi A, Siniscalchi C, Mastromarino A, et al. Effect of voriconazole on a corneal abscess caused by fusarium. Acta Ophthalmol Scand. 2004;82:762-764.
40. Klont RR, Eggink CA, Rijs AJ, et al. Successful treatment of fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin Infect Dis. 2005;40:110-112.
41. Hiraoka T, Wakabayashi T, Yuichi K, et al. Ocular toxicological evaluation of micafungin ophthalmic solution in rabbit eyes. J Ocul Pharmacol Ther. 2005;21:149-156.
42. Klippenstein K, O'Day DM, Robinson RD, et al. The qualitative evaluation of the pharmacokinetics of subconjunctivally injected antifungal agents in rabbits. Cornea. 1993;12:512-516.
43. Johns KJ, O'Day DM. Pharmacologic management of keratomycoses. Surv Ophthalmol. 1988;33:178-188.
44. O'Day DM, Head WS, Robinson RD, et al. Anomalous effect of subconjunctival miconazole on Candida albicans keratitis in rabbits. Am J Ophthalmol. 1991;112:562-566.
45. Matsumoto Y, Dogru M, Goto E, et al. Successful topical application of a new antifungal agent, micafungin, in the treatment of refractory fungal corneal ulcers: report of three cases and literature review. Cornea. 2005;24:748-753.
46. Behrens-Baumann W, Uter W, Ansorg R. Experimental studies of local therapy of Candida keratomycosis with amphotericin B. Klin Monatsbl Augenheilkd. 1987;191:125-128.
47. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol. 1994;48:471-497.
48. Watabe E, Nakai T, Matsumoto S, et al. Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob Agents Chemother. 2003;47:1995-1998.